Abbreviations :

• A : Adriamycin^© (doxorubicin) or araC or L-asparaginase
• B : bleomycin or BCNU
• C : cyclophosphamide or CCNU or cisplatin or carboplatin
• D : dacarbazine or dexamethasone
• E : etoposide
• F : 5-FU or fludarabine
• G : gemcitabine
• H : hydroxydaunomycin / doxorubicin
• I : ifosfamide or irinotecan
• L : leucovorin or L-asparaginase
• M : methotrexate or Matulane^© (procarbazine) or mitomycin C or mesna or mechlorethamine
• N : Novantrone^© (mitoxantrone)
• O : Oncovin^© (vincristine)
• P : prednisone or procarbazine or Platinol^© (cisplatin) or PS-341 / bortezomib
• Q : /
• R : rituximab
• S : Solu-Medrol (methylprednisolone)
• T : tamoxifen or thalidomide or thioguanine or thiotepa or topotecan
• U : /
• V : VM-26 / teniposide or vindesine or vinblastine or vinorelbine or Velcade^© (bortezomib)

• CHOP (cyclophosphamide 750 mg/m² IV day 1, hydroxydaunomycin / doxorubicin 50 mg/m² IV day 1, Oncovin^© (vincristine) 1.4 mg/m² (maximum 2 mg) IV day 1, prednisone 100 mg/day PO days 1-5. Repeat cycle every 21 days. Patients with initial bulky disease received 36 Gy radiotherapy to these areas irrespective of the results of chemotherapy. CNS prophylaxis was recommended for patients with lymphoblastic disease and consisted of methotrexate 15 mg intratechal on days 1, 4 of the first chemotherapy cycle and a whole brain radiotherapy with 25.2 Gy given after the end of chemotherapy. Leukopenia grade 3-4 (61-75 years : 72%; 15-60 years : 34%) or grade 4 (91%), grade 4 febrile neutropenia (47%), anemia (61-75 years : 13%; 15-60 years : 4%), grade 3-4 infection (61-75 years : 8%; 15-60 years : 4%), thrombocytopenia (61-75 years : 5%; 15-60 years : 2%), mucositis (2%; 15-60 years : 3%), alopecia (24%; 61-75 years : 63%; 15-60 years : 64%), nausea/vomiting (16%; 61-75 years : 8%; 15-60 years : 12%), diarrhea (2%), pulmonary toxicity (61-75 years : 4%), cardiotoxicity (2%; 61-75 years : 3%; 15-60 years < 1%), neurologic toxicity (7%; 61-75 years : 3%) => median relative dose intensity was 97% (61-75 years), median relative dose intensity was 98% (15-60 years), RBC transfusions necessary in 25% of patients (61-75 years), RBC transfusions necessary in 4% of patients (15-60 years), platelet transfusions necessary in 2% of patients aged 61-75 years and < 1% of patients aged 15-60 years, intravenous antibiotic therapy necessary in 38% of patients aged 61-75 years, and 25% of patients aged 15-60 years^ref. Among 418 patients treated in 3 consecutive national phase III studies, the rate of complete remission was 53% and the survival rate was 30% after 12 years of follow-up (Coltman CA, Dahlberg S, Jones SE, et al. Southwest Oncology Group studies in diffuse large cell lymphoma: a subset analysis. In: Kimura K, ed. Cancer chemotherapy: challenges for the future. Tokyo, Japan: Excerpta Medica, 1988:194-202; Bjorkholm et al. Blood 94 (1999) 599a)
• first-generation regimens (FGR), which generally included 4 chemotherapeutic agents, produced complete remission in 45 to 55 percent of patients and cure in approximately 30-35%^{ref1, ref2, ref3} (Coltman CA, Dahlberg S, Jones SE, et al. Southwest Oncology Group studies in diffuse large cell lymphoma: a subset analysis. In: Kimura K, ed. Cancer chemotherapy: challenges for the future. Tokyo, Japan: Excerpta Medica, 1988:194-202)
• BACOP (bleomycin, Adriamycin^©, cyclophosphamide, Oncovin^© (vincristine), prednisone)
• CHVmP / CHVP (cyclophosphamide 600 mg/m² IV d1, hydroxydaunomycin / doxorubicin 50 mg/m² IV d1, VM-26 / teniposide 60 mg/m² IV d1 and prednisone PO d1-5 ) repeated every 3 weeks
• CHVP : cyclophosphamide 750 mg/m² i.v. infusion, hydroxydaunomycin / doxorubicin 25 mg/m² i.v., and vindesine 3 mg/m² i.v. on day 1, prednisone 50 mg/m² on days 1–5^ref
• CHVmP/BV (CHVmP with bleomycin 6 mg/m² IM/IV and vincristine 1.4 mg/m² IV added at mid-cycle (d15))
• COMLA (cyclophosphamide 1.5 g/m² day 1; Oncovin^© (vincristine)1.4 mg/m² days 1, 8, and 15; methotrexate 120 mg/m² days 22, 29, 36, 43, 50, 57, 64, and 71; and leucovorin 25 mg/m² every 6 hours X 4, beginning 24 hours after methotrexate; and cytosine arabinoside 300 mg/m²)^ref
• COPP (CCNU, Oncovin^© (vincristine), procarbazine, prednisone OR cyclophosphamide, Oncovin^© (vincristine), procarbazine, prednisone)
• COPP-ABVD (bleomycin 10 mg/m² on days 29, 43, Adriamycin^© (doxorubicin) 25 mg/m² on days 29, 43, cyclophosphamide 650 mg/m² on days 1, 8, Oncovin^© (vincristine) 1.4 mg/m² days 1, 8, procarbazine 100 mg/m² on days 1-14, prednisone 40 mg/m² on days 1-14, vinblastine 6 mg/m² on days 29, 43, dacarbazine 375 mg/m² on days 29, 43). Leukopenia grade 3 (52%) and 4 (19%), thrombocytopenia grade 3 (4%) or 4 (2%), anemia grade 3 (4%) or 4 (1%), infection grade 3 (2%) or 4 (1%), grade 3-4 mucositis (1%), respiratory tract effects (2%), nausea (20%), digestive tract effects (3%), neurologic effects (4%), skin effects (1%), pain (2%), hair loss (36%)^ref
• second-generation CHOP-like regimens (SGR) used 6-8 chemotherapeutic drugs^ref
• CAVPE (cyclophosphamide, Adriamycin^© (doxorubicin), vincristine, prednisone and etoposide)
• COP-BLAM (cyclophosphamide, Oncovin^© (vincristine), prednisone, bleomycin, Adriamycin^© (doxorubicin), Matulane^© (procarbazine))
• COP-BLAM I : cyclophosphamide 700 mg/m² IV day 1, Oncovin^© (vincristine)  1 mg/m₂ IV  days 1 and 15 in cycles 1 through 3, day 1 only in cycles 4 through 6, prednisone 50 mg/m2 PO days 1 through 7, bleomycin 15 mg IV day 15, Adriamycin^© (doxorubicin) 60 mg/m₂ IV  day 1, Matulane^© (procarbazine) 100 mg/m² PO days 1 through 7). Mesna (400 mg IV) was administered as a uroprotective

agent 0, 4, and 8 hours after CY. Courses were repeated every 3 weeks unless delayed by hematologic toxicity or infection. Cycles were delayed for 3 to 7 days if white blood cell counts (WBC) were < 2.5 X 10⁹/L or platelets < 75 X 10⁹/L on day 22. If these limits were not reached by day 28 of a cycle, but WBCs were higher than 2 X 10⁹/L and platelets higher than 50 X 10⁹/L, treatment was continued with a reduced dose (75% of scheduled dose for CY, DOX, VR, PROC). If these lower limits were not achieved, treatment was delayed for a further week and a BM cytology control performed^{ref1, ref2}
• COP-BLAM II :
• COP-BLAM III^ref :
• COP-BLAM V
• THP-COPBLM
• M-BACOD (high-dose methotrexate, bleomycin, Adriamycin^©, cyclophosphamide, Oncovin^© (vincristine), dexamethasone). the projected 5-year survival rate for both m-BACOD and M-BACOD is now 54%^ref, much lower than the initially projected rate of 64%^ref
• m-BACOD :
• standard dose : moderate-dose methotrexate IV 200 mg/m² day 15, bleomycin IV 4 U/m² day 1, Adriamycin^© IV 45 mg/m² day 1, cyclophosphamide IV 600 mg/m² day 1, Oncovin^© (vincristine) 1.4 mg/m² day 1, dexamethasone PO 6 mg/m² days 1-5, GM-CSF SC 5 mg/kg days 4-13
• low dose for HIV-associated NHL : methotrexate IV 200 mg/m² day 15, bleomycin IV 4 U/m² day 1, Adriamycin^© IV 25 mg/m² day 1, cyclophosphamide IV 300 mg/m² day 1, Oncovin^© (vincristine) 1.4 mg/m² day 1, dexamethasone PO 3 mg/m² days 1-5^ref
Meningeal lymphoma prophylaxis in cycle 1 only : cytarabine 50 mg, IT days 1, 8, 15 and 22
Pneumocystis prophylaxis : trimethoprim/sulfamethoxazole, dapsone or inhaled pentamidine
• third-generation CHOP-like regimens (SGR) : initially, each of these centers reported complete-remission rates of 70 to 85% and predicted long-term survival of 55 to 65%, but follow-up was limited and these new treatment programs were more difficult to administer, more toxic, and more costly. Because overall survival and survival without treatment failure in the CHOP group were not significantly different from survival in the three other groups, and because the rate of severe toxic reactions and the cost of the CHOP regimen are lower, CHOP remains the best available treatment for patients with advanced-stage, intermediate-grade or high-grade non-Hodgkin's lymphoma^ref.
• MACOP-B (methotrexate 100 mg/m² IV bolus or 300 mg/m² IV over 4 hours on days 8, 36, and 64, Adriamycin^© (doxorubicin) 50 mg/m² (round to nearest 1 mg) IV on days 1, 15, 29, 43, 57, and 71, cyclophosphamide 350 mg/m² (round to nearest 10 mg) IV on days 1, 15, 29, 43, 57, and 71, Oncovin^© (vincristine) (round to nearest 0.1 mg) 1.4 mg/m² IV on days 8, 22, 36, 50, 64, and 78, prednisone 75 mg PO daily for 10 weeks, then taper over next 15 days (outpatient prescription in multiples of 5 mg or 50 mg tablets), bleomycin 10 units/m² IV on days 22, 50, and 78 (round to nearest 1 units; leucovorin 15 mg PO q6h for 6 doses, starting 24 hours after methotrexate). weekly treatment for a total of 12 weeks. Grade 4 neutropenia (21%), grade 3/4 infections (11%), grade 4 thrombocytopenia (2%), grade 3/4 mucositis (26%), endocrinological (5%), neurologic (8%), cutaneous (3%)^{ref1, ref2}
• renal dysfunction : creatinine clearance
• 0.2-0.8 ml/sec : reduce methotrexate to 50% dose and bleomycin to 75% dose
• < 0.3 ml/sec : reduce cyclophosphamide to 50% dose
• < 0.2 ml/sec : omit methotrexate dose and reduce bleomycin to 50% dose
• hepatic dysfunction : bilirubin (mmol/l)
• 1-2X ULN : reduce doxorubicin to 50% dose and vincristine to 50% dose
• 2-4X ULN : reduce doxorubicin to 25% dose and vincristine to 25% dose
• 2-3X ULN : reduce methotrexate to 75% dose
• >3X ULN : omit methotrexate dose
• >4X ULN : omit doxorubicin dose
• neurotoxicity :
• mild motor neuropathy : reduce vincristine to 2/3 dose
• moderate motor neuropathy : reduce vincristine to 2/3 dose
• severe motor neuropathy : stop treatment with vincristine
Survival among patients treated with MACOP-B^ref, initially 76%, subsequently fell to 65%^ref.
• ProMACE-CytaBOM (prednisone 60 mg/m²/day PO days 1-14, methotrexate, doxorubicin (Adriamycin^©) 25 mg/m² IV day 1, cyclophosphamide 650 mg/m² IV day 1, etoposide 120 mg/m² IV day 1, cytarabine 300 mg/m² IV day 8, bleomycin 5 units/m² IV day 8, Oncovin^© (vincristine) 1.4 mg/m² IV day 8, methotrexate 120 mg/m² IV day 8, leucovorin calcium 25 mg/m² PO every 6 hours for 4 doses beginning 24 hours after methotrexate, trimethoprim/sulfamethoxazole 2 DS PO BID. Repeat cycle every 21 days. Appropriate premedications. Grade 4 febrile neutropenia (20%), clinically documented infection (13%), culture-positive infection (20%), tumor lysis syndrome (16%), coagulopathy (12%), GI bleeding (5%), toxic mortality (6%), delivered dose 83%, 61% requiring RBC transfusion, hospitalization 63%, significant infectious complications (10%), Pneumocystis carinii pneumonia (PCP) (8%), platelet transfusions (7%))^{ref1, ref2} (Fisher RI, DeVita VT Jr, Hubbard SM, et al. Randomized trial of ProMACE-MOPP vs. ProMACE-CytaBOM in previously untreated, advanced stage, diffuse aggressive lymphomas. Proc Am Soc Clin Oncol 1984;3:242). Long-term survival  fell from 65% to 50% after 9 years of follow-up^ref
• ABC (Adriamycin^©, BCNU, cyclophosphamide)
• ABCD (Adriamycin^©, bleomycin, CCNU and dacarbazine)
• ABCM (Adriamycin^©, bleomycin, cyclophosphamide, mitomycin C)
• ACVBP (Adriamycin^© (doxorubicin) 75 mg/m² on day 1, cyclophosphamide 1200 mg/m² intravenously on day 1, vindesine 2 mg/m² on days 1 and 5, bleomycin 10 mg) on days 1 and 5, and prednisone 60 mg/m² orally from day 1 to day 5, and intrathecal methotrexate (15 mg) on day 2. Granulocyte-macrophage or G-CSF was administered subcutaneously on days 6 through 13 of each cycle. Repeat every 21 days for 4 courses. Patients then received a sequential consolidation therapy with 2 courses of intravenous methotrexate (3 g/m²) plus leucovorin rescue, 4 courses of etoposide (300 mg/m²) and ifosfamide (1500 mg/m²) with mesna protection, and 2 courses of mesna (100 mg/m²) subcutaneously for 4 days, each consolidation course being administered at a 14-day interval^ref)
• ABD (Adriamycin^© (doxorubicin), bleomycin, DTIC)
• ABDIC (Adriamycin^© (doxorubicin), bleomycin, dacarbazine, CCNU and prednisone)
• ABDV (Adriamycin^© (doxorubicin), bleomycin, DTIC, vinblastine)
• ABOS (Adriamycin^© (doxorubicin), bleomycin sulfate, vincristine, streptozocin)
• ABP (Adriamycin^© (doxorubicin), bleomycin, prednisone)
• ABV (actinomycin-D, bleomycin, vincristine)
• ABV (Adriamycin^© (doxorubicin), bleomycin, vinblastine)
• ABVD (Adriamycin^© (doxorubicin) 25 mg/m² i.v. at day 1 and 15, bleomycin 10 mg/m² i.v. at day 1 and 15, vincristine 6 mg/m² i.v. at day 1 and 15, dacarbazine 375 mg/m² i.v. at day 1 and 15). Repeat cycle every 28 days. Grade 3-4 neutropenia (21%), grade 3-4 neutropenic fever (2%), grade 3-4 anemia (5%), grade 3-4 infection (2%), grade 4 thrombocytopenia (5%), grade 3-4 nausea/vomiting (33%), grade 3 alopecia (24%), grade 3-4 pulmonary toxicity (6%), grade 3-4 peripheral neuropathy (1%) => death due to pulmonary toxicity (3%), > 80% of patients received full-dose doxorubicin. Emetogenic potential days 1, 15 level 5^{ref1, ref2}
• ABVd (Adriamycin^© (doxorubicin) 25 mg/m² i.v. at day 1 and 15, bleomycin 9 mg/m² (max 15 mg) i.v. at day 1 and 15, vinblastine 6 mg/m² (max 10 mg) i.v. at day 1 and 15, dacarbazine 250 mg/m² drip i.v. at day 1 and 15)^ref
• ABVE (Adriamycin^© (doxorubicin), bleomycin, vincristine, etoposide)
• ABVP (Adriamycin^© (doxorubicin), bleomycin sulfate, VM-26 / teniposide, prednisone)
• ABVP (Adriamycin^© (doxorubicin), bleomycin sulfate, vinblastine, prednisone or Adriamycin^© (doxorubicin), bleomycin sulfate, vincristine, prednisone)
• AC (Adriamycin^© (doxorubicin), carmustine)
• AC (Adriamycin^© (doxorubicin), CCNU)
• AC (Adriamycin^© (doxorubicin), cisplatin)
• Ac-D-Ac (Adriamycin^©, daunorubicin, Adriamycin^©)
• ACe (Adriamycin^© (doxorubicin), cyclophosphamide)
• ACE (Adriamycin^© (doxorubicin), cyclophosphamide, etoposide)
• ACFUCY (actinomycin-D, 5-FU, cyclophosphamide)
• ACID (Adriamycin^© (doxorubicin), cyclophosphamide, imidazole, dactinomycin)
• ACM (Adriamycin^© (doxorubicin), cyclophosphamide, methotrexate)
• ACOAP (AdriamycAdriamycin^© (doxorubicin)in^©, cyclophosphamide, Oncovin^© (vincristine), cytosine arabinoside, prednisone)
• ACOP (Adriamycin^© (doxorubicin), cyclophosphamide, Oncovin^© (vincristine), prednisone)
• ACOPP (Adriamycin^©, cyclophosphamide, Oncovin^© (vincristine), prednisone, procarbazine)
• ACT-FU-Cy (actinomycin-D, 5-FU, cyclophosphamide)
• ADBC (Adriamycin^© (doxorubicin), DTIC, bleomycin, CCNU)
• ADE (ara-C, daunorubicin, etoposide)
• ADIC (Adriamycin^©, DTIC)
• ADOC (Adriamycin^© (doxorubicin), cisplatin, vincristine, cyclophosphamide)
• AdOAP (Adriamycin^© (doxorubicin), Oncovin^© (vincristine), ara-C, prednisone)
• AdOP (Adriamycin^© (doxorubicin), Oncovin^© (vincristine), prednisone)
• Adria-L-PAM (Adriamycin^© (doxorubicin), L-phenyl-alanine mustard)
• AFM (Adriamycin^© (doxorubicin), 5-FU, methotrexate)
• AID (Adriamycin^© (doxorubicin), ifosfamide, dacarbazine, mesna)
• AIM (L-asparaginase, ifosfamide, methotrexate)
• ALOMAD (Adriamycin^© (doxorubicin), Leukeran^© (chlorambucil), Oncovin^© (vincristine), methotrexate, actinomycin-D, dacarbazine)
• AOPA (ara-C, Oncovin^© (vincristine), prednisone, L-asparaginase)
• AOPE (Adriamycin^© (doxorubicin), Oncovin^© (vincristine), prednisone, etoposide)
• APC (AMSA, prednisone, chlorambucil)
• APE (Adriamycin^©, Platinol^©Platinol^© (cisplatin), etoposide or ara-C, Platinol^© (cisplatin)^© (cisplatin), etoposide)
• APO (Adriamycin^©, prednisone, Oncovin^© (vincristine))
• alternating triple therapy (ATT) regimen (CHOD-Bleo, ESHAP, and NOPP continued for a total of 12 cycles, 4 of each regimen)^ref

drugs	dose (mg/m2)	days	route	treatment interval (d)
CHOD-Bleo15				21
Cyclophosphamide	750	1	IV
Doxorubicin	50 (total)	1-2	IV, CI
Vincristine	1.4 (total)	1-2	IV, CI
Bleomycin	4	1	IV
Bleomycin	10 (total)	1-2	IV, CI
Dexamethasone	40 (daily)	1-4	PO
ESHAP				21
Etoposide	40 (daily)	1-4	I.V
Methylprednisolone	500 (daily)	1-5	IV
Cytarabine	2000	5	IV (2-hour infusion after platinum)
Cisplatin	100 (total)	1-4	IV, CI
NOPP				28
Mitoxantrone	10	1	IV
Vincristine	1.4	1	IV
procarbazine	100 (daily)	1-14	PO
Prednisone	100 (daily)	1-5	PO

• AV ( Adriamycin^©, vincristine)
• AVAD (doxorubicin, vincristine, cytarabine, dexamethasone)
• AVM (Adriamycin^©, vinblastine, methotrexate or Adriamycin^©, vincristine, mitomycin C)
• AVP (actinomycin-D, vincristine, Platinol^© (cisplatin) or Adriamycin^©, vincristine, procarbazine)
• BAC (BCNU, cytarabine, cyclophosphamide)
• BACO (bleomycin, Adriamycin^©, CCNU, Oncovin^©(vincristine))
• BACOD (bleomycin, Adriamycin^©, cyclophosphamide, Oncovin^© (vincristine), dexamethasone)
• BACON ( bleomycin, Adriamycin^©, CCNU, Oncovin^© (vincristine), nitrogen mustard)
• BACT (BCNU, ara-C, cyclophosphamide, thioguanine or bleomycin, Adriamycin^©, cyclophosphamide, tamoxifen)
• BAMON (bleomycin, Adriamycin^©, methotrexate, Oncovin^© (vincristine), nitrogen mustard)
• BAP (bleomycin, Adriamycin^©, prednisone)
• BAPP (bleomycin, doxorubicin, cisplatin, prednisone)
• BAVIP (bleomycin, Adriamycin^©, vinblastine, imidazole carboxamide, prednisone)
• BBVP-M (BCNU, bleomycin, VePesid^© (etoposide), prednisone, methotrexate)
• BCAP (BCNU, cyclophosphamide, Adriamycin^©, prednisone)
• BCAVe (bleomycin, CCNU, Adriamycin^©, Velban^© (vinblastine))
• BCD (bleomycin, cyclophosphamide, dactinomycin)
• B-CHOP (bleomycincyclophosphamide, hydroxydaunomycin / doxorubicin, Oncovin^© (vincristine), prednisone)
• BCMF (bleomycin, cyclophosphamide, methotrexate, 5-FU)
• BCOP (BCNU, cyclophosphamide, Oncovin^© (vincristine), prednisone)
• BCP (BCNU, cyclophosphamide, prednisone)
• BCVP (BCNU, cyclophosphamide, vincristine, prednisone)
• BCVPP (BCNU, cyclophosphamide, vinblastine, procarbazine, prednisone)
• BCVPP-bleo (BCNU, cyclophosphamide, vinblastine, procarbazine, bleomycin)
• B-DOPA ( bleomycin, dacarbazine, Oncovin^© (vincristine), prednisone, Adriamycin^©)
• BEAC (BCNU, etoposide, ara-C, cyclophosphamide)
• BEACOPP^{ref1, ref2} : the regimen is repeated on day 22
• standard dose (bleomycin 10 mg/m² day 8, etoposide 100 mg/m² days 1-3, Adriamycin^© (doxorubicin) 25 mg/m² day 1, cyclophosphamide 650 mg/m² day 1, vincristine 1.4 mg/m² (maximum 2 g) day 8, procarbazine 100 mg/m² days 1-7, prednisone 40 mg/m² days 1-14). Leukopenia grade 3 (36%) and 4 (37%), thrombocytopenia grade 3 (6%) or 4 (3%), anemia grade 3 (16%) or 4 (1%), infection grade 3 (13%) or 4 (3%), grade 3-4 mucositis (2%), respiratory tract effects (5%), nausea (12%), digestive tract effects (2%), neurologic effects (5%), skin effects (1%), pain (3%), hair loss (75%)
• increased-dose (bleomycin 10 mg/m² day 8, etoposide 200 mg/m² days 1-3, Adriamycin^© (doxorubicin) 35 mg/m² day 1, cyclophosphamide1200 mg/m² day 1, vincristine 1.4 mg/m² (maximum 2 g) day 8, procarbazine 100 mg/m² days 1-7, prednisone 40 mg/m² days 1-14). Leukopenia grade 3 (8%) and 4 (90%), thrombocytopenia grade 3 (23%) or 4 (47%), anemia grade 3 (51%) or 4 (15%), infection grade 3 (14%) or 4 (8%), grade 3-4 mucositis (8%), respiratory tract effects (4%), nausea (20%), digestive tract effects (4%), neurologic effects (4%), skin effects (4%), pain (9%), hair loss (79%)
• BEAM (BCNU 300 mg/m²_BSA, etoposide 1600 (1200 ?^ref) mg/m²_BSA, cytarabine 1600 mg/m²_BSA, melphalan140 mg/m²_BSA)
• BEMP (bleomycin, Eldisine^© (vindesine), mitomycin C, Platinol^©Platinol^© (cisplatin))
• BHD (BCNU, hydroxyurea (HU), dacarbazine)
• BHDV (BCNU, hydroxyurea (HU), dacarbazine, vincristine)
• BIP (bleomycin, ifosfamide, Platinol^© (cisplatin))
• BLEO-COMF (bleomycin, cyclophosphamide, Oncovin^© (vincristine), methotrexate, 5-FU)
• BLEO-MOPP (bleomycin, nitrogen mustard, Oncovin^© (vincristine), procarbazine, prednisone)
• BLEO-COMF (bleomycin, cyclophosphamide, Oncovin^© (vincristine), methotrexate, 5-FU)
• BLEO-MOPP (bleomycin, nitrogen mustard, Oncovin^© (vincristine), procarbazine, prednisone)
• BOAP (bleomycin, Oncovin^© (vincristine), Adriamycin^©, prednisone)
• BOLD (bleomycin, Oncovin^© (vincristine), lomustine, dacarbazine)
• BOMES (BCNU, vincristine, methotrexate, etoposide, and methylprednisolone)
• BOMP (bleomycin, Oncovin^© (vincristine), Matulane^© (procarbazine), prednisone)
• BONP (bleomycin, Oncovin^© (vincristine), Natulan^© (procarbazine), prednisolone)
• BOP (BCNU, Oncovin^© (vincristine), prednisone)
• BOP (bleomycin, Oncovin^© (vincristine), Platinol^© (cisplatin))
• BOPAM (bleomycin, Oncovin^© (vincristine), prednisone, Adriamycin^©, mechlorethamine, methotrexate)
• BOPP (BCNU, Oncovin^© (vincristine), procarbazine, prednisone)
• BR : bendamustine 90 mg/m² as a 30-minute infusion on days 1 and 2, rituximab 375 mg/m² IV on day 1, for a maximum of four cycles every 4 weeks^ref
• BuCy (busulfan, cyclophosphamide)
• BuEtoposide (etoposide)
• BVAC : high-dose carmustine 600 mg/m², etoposide 1600 mg/m², cytarabine 24 g/m², and cyclophosphamide 90 mg/kg
• BVAP (BCNU, vincristine, Adriamycin^©, prednisone)
• BVCPP (BCNU, vinblastine, cyclophosphamide, procarbazine, prednisone)
• BVD (BCNU, vincristine, dacarbazine)
• BVDS (bleomycin, Velban^© (vinblastine), doxorubicin, streptozocin)
• BVPP (BCNU, vincristine, procarbazine, prednisone)
• CA (cyclophosphamide, Adriamycin^©)
• CABOP, CA-BOP (cyclophosphamide, Adriamycin^©, bleomycin, Oncovin^© (vincristine), prednisone)
• CABS (BCNU, Adriamycin^©, bleomycin, streptozocin)
• CAC (cisplatin, ara-C, caffeine)
• CAD (cyclophosphamide, Adriamycin^©, dacarbazine OR cytosine arabinoside, daunorubicin OR cyclophosphamide, Adriamycin^©, dexamethasone)
• CADIC ( cyclophosphamide, Adriamycin^©, DTIC )
• CAE (cyclophosphamide, Adriamycin^©, etoposide)
• CAF (cyclophosphamide, Adriamycin^©, 5-FU)
• CAFFI (cyclophosphamide, Adriamycin^©, 5-FU by continuous infusion)
• CAFP (cyclophosphamide, Adriamycin^©, 5-FU, prednisone)
• CAFTH (cyclophosphamide, Adriamycin^©, 5-FU, tamoxifen, Halotestin^© (fluoxymesterone))
• CAFVP (cyclophosphamide, Adriamycin^©, 5-FU, vincristine, prednisone)
• CALF (cyclophosphamide, Adriamycin^©, leucovorin calcium, 5-FU)
• CALF-E (cyclophosphamide, Adriamycin^©, leucovorin calcium, 5-FU, ethinyl estradiol)
• CAM (cyclophosphamide, Adriamycin^©, methotrexate)
• CAMB (cyclophosphamide, Adriamycin^©, methotrexate, bleomycin)
• CAMELEON (cytosine arabinoside, high-dose methotrexate, leucovorin calcium, Oncovin^© (vincristine))
• CAMEO (cyclophosphamide, Adriamycin^©, methotrexate, etoposide, Oncovin^© (vincristine))
• CAMF (cyclophosphamide, Adriamycin^©, methotrexate, 5-FU or cyclophosphamide, Adriamycin^©methotrexate, leucovorin / folinic acid calcium)
• CAMLO (cytosine arabinoside, methotrexate, leucovorin calcium, Oncovin^© (vincristine))
• CAMP (cyclophosphamide, Adriamycin^©, methotrexate, procarbazine)
• CAO (cyclophosphamide, Adriamycin^©, Oncovin^© (vincristine))
• CAP (cyclophosphamide, Adriamycin^©, Platinol^© (cisplatin) or cyclophosphamide, Adriamycin^©, prednisone)
• CAP-I (cyclophosphamide, Adriamycin^©, Platinol^© (cisplatin))
• CAP-II (cyclophosphamide, Adriamycin^©, high-dose Platinol^© (cisplatin))
• CAP-BOP (cyclophosphamide, Adriamycin^©, procarbazine, bleomycin, Oncovin^© (vincristine), prednisone)
• CAPPr (cyclophosphamide, Adriamycin^©, Platinol^© (cisplatin), prednisone)
• CAT (cytosine arabinoside, Adriamycin^©, thioguanine or cytosine arabinoside, thioguanine)
• CAV (cyclophosphamide, Adriamycin^©, Velban^© (vinblastine) or cyclophosphamide, Adriamycin^©, vincristine)
• CAVe, CA-Ve (CCNU, Adriamycin^©, Velban^© (vinblastine))
• CAVP (cyclophosphamide, Adriamycin^©, VM-26 / teniposide, prednisone)
• CAVP-I (cyclophosphamide, Adriamycin^©, vincristine